Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Published 06/01/2023, 18:16
Updated 06/01/2023, 19:41
© Reuters.  Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session

© Reuters. Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga - Gainers

  • Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
  • Spruce Biosciences, Inc. (NASDAQ: SPRB) shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan.
  • MedAvail Holdings, Inc. (NASDAQ: MDVL) gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share.
  • CytomX Therapeutics, Inc. (NASDAQ: CTMX) climbed 46.4% to $2.6198. CytomX and Moderna (NASDAQ:MRNA) reported a strategic research collaboration for mRNA-based conditionally activated therapeutics.
  • Zomedica Corp. (NYSE: ZOM) gained 38% to $0.2649 after Dawson James initiated coverage on the stock with a Buy rating and a $6 price target.
  • Aehr Test Systems (NASDAQ: AEHR) shares jumped 34.8% to $23.28 after the company reported better-than-expected Q2 EPS and sales results and announced it received a follow-on production order from its second major silicon carbide semiconductor customer for an additional production FOX-XP multi-wafer test and burn-in system configured with Aehr's fully integrated and automated WaferPak Aligner.
  • Tantech Holdings Ltd (NASDAQ: TANH) gained 26.8% to $3.1980. Tantech Hldgs recently posted H1 sales of $27.00 million.
  • Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) gained 26% to $0.7555.
  • Aligos Therapeutics, Inc. (NASDAQ: ALGS) jumped 23.2% to $1.22 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $2.5 to $3.
  • Infobird Co., Ltd (NASDAQ: IFBD) surged 23% to $0.9476.
  • Kidpik Corp. (NASDAQ: PIK) gained 22.2% to $0.8799.
  • Sight Sciences, Inc. (NASDAQ: SGHT) gained 21.8% to $14.39. Stifel upgraded Sight Sciences from Hold to Buy and raised the price target from $10 to $15.
  • Mobile Global Esports Inc. (NASDAQ: MGAM) rose 21.5% to $1.30 after gaining over 21% on Thursday.
  • Schmitt Industries, Inc. (NASDAQ: SMIT) gained 21.3% to $0.3399.
  • EZGO Technologies Ltd. (NASDAQ: EZGO) gained 19.5% to $0.99.
  • Zynex, Inc. (NASDAQ: ZYXI) gained 19.4% to $16.89. Piper Sandler upgraded Zynex from Neutral to Overweight and raised the price target from $10 to $18.
  • CureVac N.V. (NASDAQ: CVAC) surged 18.2% to $7.54 after the company announced data on joint COVID-19 and flu mRNA vaccine development programs.
  • World Wrestling Entertainment, Inc. (NYSE: WWE) rose 17.6% to $84.69 after Vince McMahon announced he has taken actions in support of a plan for WWE to undertake a review of strategic alternatives and capture unique opportunity to maximize long-term value.
  • Oxbridge Re Holdings Limited (NASDAQ: OXBR) gained 16.8% to $1.80.
  • Sensus Healthcare, Inc. (NASDAQ: SRTS) jumped 16.6% to $8.60. Sensus Healthcare expects Q4 sales to exceed $13 million.
  • TCR2 Therapeutics Inc. (NASDAQ: TCRR) gained 16.5% to $1.27. Piper Sandler maintained TCR2 Therapeutics with an Overweight and raised the price target from $8 to $10.
  • Magic Empire Global Limited (NASDAQ: MEGL) rose 13.9% to $2.6199 after climbing 75% on Thursday.
  • Mullen Automotive, Inc. (NASDAQ: MULN) gained 13.8% to $0.4762.
  • Aethlon Medical, Inc. (NASDAQ: AEMD) shares rose 13.2% to $0.39. Aethlon Medical, last month, posted a Q2 loss of $0.18 per share.
  • Duck Creek Technologies, Inc. (NYSE: DCT) gained 12.5% to $12.69 following Q1 results.
  • Amarin Corporation plc (NASDAQ: AMRN) gained 12.3% to $1.4150 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.3 to $3.
  • JinkoSolar Holding Co., Ltd. (NYSE: JKS) rose 11.8% to $44.69.
  • Immunome, Inc. (NASDAQ: IMNM) shares gained 11.2% to $5.24 after the company and AbbVie (NYSE:ABBV) announced a strategic collaboration to discover multiple novel oncology targets. Immunome will receive a $30 million upfront payment with the potential for milestones and royalties.
  • Oriental Culture Holding LTD (NASDAQ: OCG) gained 10% to $0.55.
  • eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 8% to $0.5958. eFFECTOR Therapeutics provided an update on its ongoing clinical development programs for zotatifin, in Phase 2 expansion cohorts for estrogen receptor-positive breast cancer (ER+ BC) and KRAS non-small cell lung cancer (KRAS NSCLC) as well as Phase 1 development for COVID-19, and tomivosertib, in Phase 2b trial for non-small cell lung cancer (NSCLC) in combination with pembrolizumab.
Losers
  • Fate Therapeutics, Inc. (NASDAQ: FATE) shares dipped 62.2% to $4.16 after the company announced termination
  • of its collaboration agreement with Janssen, pipeline prioritization, next-generation programs and key 2023 initiatives.
  • Graphite Bio, Inc. (NASDAQ: GRPH) fell 41.3% to $1.7950 after the company reported it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.
  • Atai Life Sciences N.V. (NASDAQ: ATAI) fell 41.3% to $1.5450 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.
  • Nabriva Therapeutics plc (NASDAQ: NBRV) dropped 33.4% to $1.5238 after the company issued a corporate update.
  • AnaptysBio, Inc. (NASDAQ: ANAB) declined 28.8% to $21.49 after the company announced portfolio update across best-in-class immune cell modulating antibodies. Raymond James downgraded AnaptysBio from Outperform to Market Perform.
  • NextPlay Technologies, Inc. (NASDAQ: NXTP) fell 25.9% to $1.63. NextPlay announced a 1-for-20 reverse stock split effective January 6, 2023.
  • Landos Biopharma, Inc. (NASDAQ: LABP) fell 24.7% to $0.4086 after Jefferies downgraded the stock from Hold to Underperform and lowered its price target from $0.20 to $0.10.
  • AMTD Digital Inc. (NYSE: HKD) shares fell 24.5% to $22.54 after surging around 200% on Thursday.
  • Elevation Oncology, Inc. (NASDAQ: ELEV) declined 20% to $0.8395 after the company reported pipeline prioritization, realignment of resources to advance EO-3021 and CEO transition.
  • Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) dropped 20% to $2.60.
  • Vivos Therapeutics, Inc. (NASDAQ: VVOS) dropped 19.1% to $1.52. Vivos Therapeutics priced an $8 million private placement at $1.20 per unit.
  • Moolec Science SA (NASDAQ: MLEC) declined 17.8% to $4.50.
  • Genprex, Inc. (NASDAQ: GNPX) dropped 17.6% to $1.4225.
  • Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 16.9% to $1.4050 after dropping around 30% on Thursday. The company said it will miss its 10-Q filing deadline for the quarter ending Nov 26, 2022 and has also concluded that there is substantial doubt about its ability to continue as a going concern.
  • Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) declined 15.4% to $3.90.
  • XPeng Inc. (NYSE: XPEV) fell 15% to $10.11.
  • Palisade Bio, Inc. (NASDAQ: PALI) dropped 14.8% to $2.76.
  • Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) fell 14.5% to $3.6913.
  • The Greenbrier Companies, Inc. (NYSE: GBX) dropped 14% to $30.00 after the company reported Q1 earnings results and issued guidance.
  • Kura Sushi USA, Inc. (NASDAQ: KRUS) fell 13% to $42.11 after the company reported worse-than-expected Q1 EPS and sales results.
  • InMed Pharmaceuticals Inc. (NASDAQ: INM) fell 13% to $1.68 after declining over 11% on Thursday.
  • Vyant Bio, Inc. (NASDAQ: VYNT) fell 12.3% to $1.06. Vyant Bio shares jumped around 57% on Thursday after the company engaged LifeSci Capital as its advisor to explore strategic alternatives.
  • Orchard Therapeutics plc (NASDAQ: ORTX) shares fell 11.3% to $0.5583. Orchard Therapeutics shares gained around 22% on Thursday after the company announced FDA clearance of the IND application for OTL-203 in MPS-IH.
  • ABVC BioPharma, Inc. (NASDAQ: ABVC) fell 11.2% to $0.9501. ABVC BioPharma shares climbed over 72% on Thursday after the company announced the FDA approved its IND submission, allowing the company to proceed with the clinical study of ABV-1519 for the treatment of non-small cell lung cancer.
  • Waters Corporation (NYSE: NYSE:WAT) declined 9.9% to $312.79. SVB Leerink maintained Waters with a Market Perform and raised the price target from $320 to $352.
  • Silvergate Capital Corporation (NYSE: SI) dropped 9.5% to $11.37 after multiple firms downgraded the stock and lowered their respective price target.
Also Check This Out Ethereum Remains Above This Key Level; TRON Becomes Top Loser

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.